A novel indole derivative, 2‐{3‐[1‐(benzylsulfonyl)piperidin‐4‐yl]‐2‐methyl‐1 H ‐indol‐1‐yl}‐1‐(pyrrolidin‐1‐yl)ethenone, suppresses hedgehog signaling and drug‐resistant tumor growth
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Joo Hyun Jung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Signal Transduction, Hedgehog Proteins, Indoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT), BK21 FOUR program.
Abstract (Originalsprache)
The Hedgehog (Hh) signaling pathway plays important roles in various physiological functions. Several malignancies, such as basal cell carcinoma (BCC) and medulloblastoma (MB), have been linked to the aberrant activation of Hh signaling. Although therapeutic drugs have been developed to inhibit Hh pathway‐dependent cancer growth, drug resistance remains a major obstacle in cancer treatment. Here, we show that the newly identified, 2‐{3‐[1‐(benzylsulfonyl)‐1,2,3,6‐tetrahydropyridin‐4‐yl]‐2‐methyl‐1 H ‐indol‐1‐yl}‐1‐(pyrrolidin‐1‐yl)ethenone analog (LKD1214) exhibits comparable potency to vismodegib in suppressing the Hh pathway activation. LKD1214 represses Smoothened (SMO) activity by blocking its ciliary translocation. Interestingly, we also identified that it has a distinctive binding interface with SMO compared with other SMO‐regulating chemicals. Notably, it maintains an inhibitory activity against the Smo D477H mutant, as observed in a patient with vismodegib‐resistant BCC. Furthermore, LKD1214 inhibits tumor growth in the mouse model of MB. Collectively, these findings suggest that LKD1214 has the therapeutic potential to overcome drug‐resistance in Hh‐dependent cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.
- College of Pharmacy, Dongguk University, Goyangsi, Gyeonggido, Korea.
Förderung
- National Research Foundation of Korea
- National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)
- BK21 FOUR program
Zitieren
APA
Jung, J. H., Lee, H., Jeon, J., Lee, Y. J., Nada, H., Kim, M., Lee, H., Bhattarai, D., Lee, K., & Ko, H. W. (2024). A novel indole derivative, 2‐{3‐[1‐(benzylsulfonyl)piperidin‐4‐yl]‐2‐methyl‐1 H ‐indol‐1‐yl}‐1‐(pyrrolidin‐1‐yl)ethenone, suppresses hedgehog signaling and drug‐resistant tumor growth. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400218
Vancouver
Jung JH, Lee H, Jeon J, Lee YJ, Nada H, Kim M, et al. A novel indole derivative, 2‐{3‐[1‐(benzylsulfonyl)piperidin‐4‐yl]‐2‐methyl‐1 H ‐indol‐1‐yl}‐1‐(pyrrolidin‐1‐yl)ethenone, suppresses hedgehog signaling and drug‐resistant tumor growth. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400218
BibTeX
@article{Jung2024,
author = {Jung, Joo Hyun and Lee, Hwayoung and Jeon, Jiyeon and Lee, Yoon Ji and Nada, Hossam and Kim, Minkyoung and Lee, Hankyu and Bhattarai, Deepak and Lee, Kyeong and Ko, Hyuk Wan},
title = {A novel indole derivative, 2‐3‐[1‐(benzylsulfonyl)piperidin‐4‐yl]‐2‐methyl‐1 H ‐indol‐1‐yl‐1‐(pyrrolidin‐1‐yl)ethenone, suppresses hedgehog signaling and drug‐resistant tumor growth},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400218}
}
EUVIMED